Form 4: Lixte Biotechnology Director Yun Yen Receives Significant Stock Option Grants
Director Compensation Disclosure
Lixte Biotechnology Holdings, Inc. Director Yun Yen was granted 21,632 stock options, with 11,632 vesting immediately in lieu of cash compensation, aligning executive interests with shareholder value.
Summary
- Director Yun Yen of Lixte Biotechnology Holdings, Inc. was granted a total of 21,632 stock options on June 30, 2025.
- One grant consisted of 10,000 options with an exercise price of $0.905, vesting in eight equal quarterly installments starting September 30, 2025, and expiring on June 30, 2030.
- A second grant of 11,632 options, also with an exercise price of $0.905, vested immediately on June 30, 2025, and expires on June 30, 2030. This grant was provided in lieu of quarterly cash compensation under the Board Compensation Plan.
- Following these transactions, Yun Yen beneficially owns a total of 81,690 options to purchase common stock and 5,263 warrants to purchase common stock.
Sentiment
Score: 7
Explanation: The filing is a routine disclosure of director compensation through stock option grants. This is generally viewed positively as it aligns the director's interests with shareholders, especially when options are granted in lieu of cash, conserving company funds. There are no negative operational or financial disclosures.
Positives
- The grant of stock options to Director Yun Yen aligns management's financial interests directly with the long-term performance of Lixte Biotechnology Holdings, Inc. and shareholder value.
- The immediate vesting of 11,632 options, granted in lieu of cash compensation, demonstrates a commitment to equity-based remuneration, potentially conserving cash for company operations.
Negatives
- No specific negative information is contained within this routine Form 4 filing.
Risks
- No specific risks are detailed in this Form 4, which primarily reports changes in beneficial ownership.
Future Outlook
The vesting schedule for 10,000 options, extending through eight equal quarterly installments starting September 30, 2025, indicates a long-term incentive structure for Director Yun Yen, aligning future performance with equity value.
Management Comments
- Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
- Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Industry Context
Granting stock options to directors is a common practice in the biotechnology industry and other sectors. It serves to attract and retain qualified board members, align their interests with those of shareholders, and incentivize long-term company performance, especially in industries with long development cycles and high R&D costs like biotech.
Comparison to Industry Standards
- The practice of compensating directors with equity, including stock options, is a standard and widely accepted corporate governance practice across various industries, including biotechnology.
- While specific comparable companies or projects are not detailed in this filing, this form of compensation is consistent with typical remuneration structures designed to align director incentives with shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Implementation | Grant of 11,632 stock options to Director Yun Yen in lieu of quarterly cash compensation, as per the Board Compensation Plan. | 06/30/2025 | Aligns director compensation more closely with equity performance and conserves cash for the company. |
Related Party Transactions
- Grant of 21,632 stock options to Yun Yen, a director of Lixte Biotechnology Holdings, Inc., constitutes a related party transaction as it involves compensation to a key management personnel.
Stakeholder Impact
- Shareholders: The equity grants to a director align their interests with shareholders, potentially leading to better long-term performance and value creation.
- Creditors: The decision to grant options in lieu of cash compensation could be seen as a positive for creditors as it conserves cash, potentially improving liquidity.
Next Steps
- Vesting of 10,000 stock options in eight equal quarterly installments, starting September 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 08/04/2018 | Date exercisable for 3,333 options to purchase common stock with an exercise price of $16.8, expiring 08/04/2023. |
| 05/22/2019 | Date exercisable for 833 options to purchase common stock with an exercise price of $66, expiring 05/22/2024. |
| 11/30/2020 | Date exercisable for 5,263 warrants to purchase common stock with an exercise price of $57, expiring 11/30/2025. |
| 01/06/2021 | Date exercisable for 5,000 options to purchase common stock with an exercise price of $32.1, expiring 01/06/2026. |
| 06/30/2021 | Date exercisable for 10,000 options to purchase common stock with an exercise price of $30.3, expiring 06/30/2026. |
| 06/30/2022 | Date exercisable for 10,000 options to purchase common stock with an exercise price of $7.45, expiring 06/30/2027. |
| 06/30/2024 | Date exercisable for 10,000 options to purchase common stock with an exercise price of $2.37, expiring 06/30/2029. |
| 06/30/2024 | Date exercisable for 4,527 options to purchase common stock with an exercise price of $2.37, expiring 06/30/2029. |
| 09/30/2024 | Date exercisable for 5,786 options to purchase common stock with an exercise price of $1.3, expiring 09/30/2029. |
| 01/20/2025 | Date exercisable for 4,545 options to purchase common stock with an exercise price of $2.33, expiring 01/20/2030. |
| 03/31/2025 | Date exercisable for 8,777 options to purchase common stock with an exercise price of $1.21, expiring 03/31/2030. |
| 06/30/2025 | Transaction date for new option grants to Yun Yen. |
| 06/30/2025 | Date exercisable for 11,632 options to purchase common stock with an exercise price of $0.905, expiring 06/30/2030 (vesting immediately). |
| 07/09/2025 | Signature date of Reporting Person Yun Yen. |
| 09/30/2025 | Start date for vesting of 10,000 options granted on 06/30/2025, vesting in eight equal quarterly installments. |
| 01/06/2026 | Expiration date for 5,000 options to purchase common stock with an exercise price of $32.1. |
| 06/30/2026 | Expiration date for 10,000 options to purchase common stock with an exercise price of $30.3. |
| 06/30/2027 | Expiration date for 10,000 options to purchase common stock with an exercise price of $7.45. |
| 06/30/2029 | Expiration date for 10,000 options to purchase common stock with an exercise price of $2.37. |
| 06/30/2029 | Expiration date for 4,527 options to purchase common stock with an exercise price of $2.37. |
| 09/30/2029 | Expiration date for 5,786 options to purchase common stock with an exercise price of $1.3. |
| 01/20/2030 | Expiration date for 4,545 options to purchase common stock with an exercise price of $2.33. |
| 03/31/2030 | Expiration date for 8,777 options to purchase common stock with an exercise price of $1.21. |
| 06/30/2030 | Expiration date for 10,000 options to purchase common stock with an exercise price of $0.905. |
| 06/30/2030 | Expiration date for 11,632 options to purchase common stock with an exercise price of $0.905. |
Keywords
LIXTE BIOTECHNOLOGY HOLDINGS, LIXT, SEC Form 4, beneficial ownership, stock options, director compensation, equity compensation, corporate governance, biotechnology, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.